不可切除或复发性转移性恶性黑色素瘤的化疗：最新进展
Chemotherapy of unresectable or recurrent metastatic malignant melanomas: an update.
作者信息
Block J B, Tabbarah H, Isacoff W, Drakes T P
出版信息
J Dermatol Surg Oncol. 1979 Feb;5(2):118-23. doi: 10.1111/j.1524-4725.1979.tb00624.x.
Abstract
Satisfactory chemotherapeutic management of malignant melanomas in advanced stages must await development of more active agents and combinations of them than are presently available. The development of entirely new means of treatment by hormones, heat, and adjuvants like amphotericin B may improve the efficacy of currently available agents.
摘要
晚期恶性黑色素瘤令人满意的化疗管理必须等待比目前可用的更有效的药物及其组合的开发。通过激素、热以及诸如两性霉素B等佐剂开发全新的治疗方法可能会提高现有药物的疗效。
相似文献
1
Chemotherapy of unresectable or recurrent metastatic malignant melanomas: an update.不可切除或复发性转移性恶性黑色素瘤的化疗：最新进展
J Dermatol Surg Oncol. 1979 Feb;5(2):118-23. doi: 10.1111/j.1524-4725.1979.tb00624.x.
2
Adjuvant chemoimmunotherapy stage I/II malignant melanoma.辅助化学免疫疗法治疗I/II期恶性黑色素瘤
J Surg Oncol. 1982 Mar;19(3):165-70. doi: 10.1002/jso.2930190311.
3
Chemotherapy of malignant melanoma.恶性黑色素瘤的化疗
World J Surg. 1979 Jul 30;3(3):321-8. doi: 10.1007/BF01556584.
4
[Chemotherapy of malignant melanomas].
Haematol Blood Transfus. 1978;21:293-302.
5
Current concepts in the management of malignant melanoma.
Am J Med Sci. 1976 Sep-Oct;272(2):185-95.
6
[Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].[福莫司汀治疗转移性恶性黑色素瘤。结果的总体分析]
Pathol Biol (Paris). 1990 Oct;38(8):876-80.
7
[Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].氮烯咪胺与卡介苗辅助化学免疫疗法治疗恶性黑色素瘤的经验（作者译）
Z Hautkr. 1982 Feb 15;57(4):294-7.
8
[Chemotherapy of malignant melanoma].[恶性黑色素瘤的化疗]
Chirurg. 1986 Oct;57(10):606-11.
9
10
The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.接受卡介苗（BCG）治疗（无论是否联合化疗）的恶性黑色素瘤患者的生存率。
Aust N Z J Surg. 1979 Jun;49(3):335-9. doi: 10.1111/j.1445-2197.1979.tb07675.x.
Zotero 插件